Prostate cancer 2004: Insights from national disease registries

ONCOLOGY

Volumn 18, Issue 10, 2004, Pages 1239-1247

  Cooperberg, Matthew R ^a   Park, Sangtae ^a   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CLINICAL TRIAL; HUMAN; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; QUALITY OF LIFE; REGISTER; REVIEW; RISK FACTOR; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; REGISTRIES; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 16644387106     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Stanford JL, Stephenson RA, Coyle LM, et al: Prostate Cancer Trends 1973-1995, SEER program. NIH Pub No. 99-4543. Bethesda, Md, National Cancer Institute, 1999.
2. Holmberg L, Bill-Axelson A, Helgesen F, et al: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781-789, 2002.
3. Steinberg GD, Bales GT, Brendler CB: An analysis of watchful waiting for clinically localized prostate cancer. J Urol 159:1431-1436, 1998.
4. Wei JT, Dunn RL, Sandier HM, et al: Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20:557-566, 2002.
5. Potosky AL, Harlan LC, Stanford JL, et al: Prostate cancer practice patterns and quality of life: The Prostate Cancer Outcomes Study. J Natl Cancer Inst 91:1719-1724, 1999.
6. Sun L, Gancarczyk KJ, Paquette EL, et al: Introduction to Department of Defense Center for Prostate Disease Research multicenter national prostate cancer database, and analysis of changes in the PSA era. Urol Oncol 6:203-209, 2001.
7. Lance RS, Freidrichs PA, Kane C, et al: A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. BJU Int 87:61-65, 2001.
8. Lubeck DP, Litwin MS, Henning JM, et al: The CaPSURE database: A methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 48:773-777, 1996.
9. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998.
10. Cooperberg MR, Lubeck DP, Mehta SS, et al: Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (Data from CaPSURE). J Urol 170:S21-S27, 2003.
11. Freedland SJ, Amling CL, Dorey F, et al: Race as an outcome predictor after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology 60:670-674, 2002.
12. Paquette EL, Sun L, Paquette LR, et al: Improved prostate cancer-specific survival and other disease parameters: Impact of prostate-specific antigen testing. Urology 60:756-759, 2002.
13. Smith EB, Frierson HF Jr, Mills SE, et al: Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: Is there evidence for systematic upgrading? Cancer 94:2282-2287, 2002.
14. Freedland SJ, Amling CL, Terris MK, et al: Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? Results from the SEARCH database. Prostate Cancer Prostatic Dis 6:261-265, 2003.
15. Hoffman RM, Gilliland FD, Eley JW, et al: Racial and ethnic differences in advanced-stage prostate cancer: The Prostate Cancer Outcomes Study. J Natl Cancer Inst 93:388-395, 2001.
16. Cooperberg MR, Lubeck DP, Penson DF, et al: Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: Data from CaPSURE. J Urol 170:905-908, 2003.
17. Grossfeld GD, Latini DM, Downs T, et al: Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol 168:2510-2515, 2002.
18. Amling CL, Kane CJ, Riffenburgh RH, et al: Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 58:723-728, 2001.
19. Oesterling JE: Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol Clin North Am 20:705-711, 1993.
20. Cooperberg MR, Lubeck DP, Grossfeld GD, et al: Contemporary trends in imaging test utilization for prostate cancer staging: Data from the cancer of the prostate strategic urologic research endeavor. J Urol 168:491-495, 2002.
21. Harlan LC, Potosky A, Gilliland FD, et al: Factors associated with initial therapy for clinically localized prostate cancer: Prostate cancer outcomes study. J Natl Cancer Inst 93:1864-1871, 2001.
22. Hoffman RM, Harlan LC, Klabunde CN, et al: Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med 18:845-853, 2003.
23. Koppie TM, Grossfeld GD, Miller D, et al: Patterns of treatment of patients with prostate cancer initially managed with surveillance: Results from the CaPSURE database. J Urol 164:81-88, 2000.
24. Harlan SR, Cooperberg MR, Elkin EP, et al: Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE. J Urol 170:1804-1807, 2003.
25. Cooperberg MR, Lubeck DP, Meng MW, et al: The changing face of low-risk prostate cancer: Trends in clinical presentation and primary managment (data from CaPSURE) (abstract 1723). J Clin Oncol 22:2141-2149, 2004.
26. Potosky AL, Knopf K, Clegg LX, et al: Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study. J Clin Oncol 19:3750-3757, 2001.
27. Cooperberg MR, Grossfeld GD, Lubeck DP, et al: National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95:981-989, 2003.
28. Penson DF, Schonfeld WH, Flanders SC, et al: Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: Results from the CAPSURE database. Urology 57:499-503, 2001.
29. Grossfeld GD, Latini DM, Lubeck DP, et al: Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: Results from CaPSURE. Urology 59:560-565, 2002.
30. Gancarczyk KJ, Wu H, McLeod DG, et al: Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: The Center for Prostate Disease Research nomograms. Urology 61:589-595, 2003.
31. Freedland SJ, Aronson WJ, Terris MK, et al: Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: Results from SEARCH database. J Urol 169:2136-2141, 2003.
32. Freedland SJ, Presti JC Jr, Terris MK, et al: Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: Results from the SEARCH database. J Urol 169:2129-2135, 2003.
33. Freedland SJ, Aronson WJ, Csathy GS, et al: Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: Results from the SEARCH database. Urology 61:742-747, 2003.
34. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer (see comments). J Urol 150:110-114, 1993.
35. Penson DF, Grossfeld GD, Li YP, et al: How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol 167:1653-1657 (discussion 1657-1658), 2002.
36. Bauer JJ, Connelly RR, Seterhenn IA, et al: Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 159:929-933, 1998.
37. Moul JW, Connelly RR, Lubeck DP, et al: Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 166:1322-1327, 2001.
38. Kattan MW, Eastham JA, Stapleton AM, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998.
39. Grossfeld GD, Latini DM, Lubeck DP, et al: Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 169:157-163, 2003.
40. D'Amico AV, Moul JW, Carroll PR, et al: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003.
41. Lubeck DP, Litwin MS, Henning JM, et al: Measurement of health-related quality of life in men with prostate cancer: The CaPSURE database. Qual Life Res 6:385-392, 1997.
42. Litwin MS, Lubeck DP, Henning JM, et al: Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database. J Urol 159:1988-1992, 1998.
43. Cooperberg MR, Koppie TM, Lubeck DP, et al: How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: Data from CaPSURE. Urology 61:190-196, 2003.
44. Potosky AL, Legler J, Albertsen PC, et al: Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92:1582-1592, 2000.
45. Penson DF, Feng Z, Kuniyuki A, et al: General quality of life 2 years following treatment for prostate cancer: What influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol 21:1147-1154, 2003.
46. Hamilton AS, Stanford JL, Gilliland FD, et al: Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: Results from the Prostate Cancer Outcomes Study. J Clin Oncol 19:2517-2526, 2001.
47. Potosky AL, Reeve BB, Clegg LX, et al: Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 94:430-437, 2002.
48. Lubeck DP, Litwin MS, Henning JM, et al: Changes in health-related quality of life in the first year after treatment for prostate cancer: Results from CaPSURE. Urology 53:180-186, 1999.
49. Litwin MS, Pasta DJ, Yu J, et al: Urinary function and bother after radical prostatectomy or radiation for prostate cancer: A longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 164:1973-1977, 2000.
50. Litwin MS, Flanders SC, Pasta DJ, et al: Sexual function and bother after radical prostatectomy or radiation for prostate cancer: Multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 54:503-508, 1999.
51. Hoffman RM, Hunt WC, Gilliland FD, et al: Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer 97:1653-1662, 2003.
52. Lubeck DP, Litwin MS, Henning JM, et al: An instrument to measure patient satisfaction with healthcare in an observational database: Results of a validation study using data from CaPSURE. Am J Manag Care 6:70-76, 2000.
53. Lubeck DP, Kim H, Grossfeld G, et al: Health related quality of life differences between black and white men with prostate cancer: Data from the cancer of the prostate strategic urologic research endeavor. J Urol 166:2281-2285, 2001.
54. Penson DF, Stoddard ML, Pasta DJ, et al: The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J Clin Epidemiol 54:350-358, 2001.